Attention deficits and inappropriate regulation of sensory signal processing are hallmarks of many neuropsychiatric conditions, including attention deficit hyperactivity, for which methylphenidate (MPH) and atomoxetine (ATX) are commonly prescribed therapeutic treatments. Despite their widespread use and known mechanism of blocking reuptake of catecholamine transmitters in the brain, the resultant actions on individual neuron and neural circuit function that lead to therapeutic efficacy are poorly understood. Given the ability of MPH and ATX to improve cognitive performance in humans and rodent assays of attention, we were interested in their influence on early sensory processing in the dorsal lateral geniculate nucleus (dLGN), the primary thalamic relay for visual information from the retina to the visual cortex. In male rats, dLGN neuronal responses to light stimuli were altered in multiple ways after doses of MPH or ATX observed to enhance performance in visually guided assays of attention (MPH = 2 mg/kg; ATX = 0.5 mg/kg). Latencies to response onset and to the peak of the primary response were decreased, while the peak intensity and area of the primary response were increased. In addition, some cells that were unresponsive to light stimuli prior to drug treatment displayed a "gating effect," wherein prominent responses to light stimuli were evident after drug administration. Our results begin to reveal unique effects of MPH and ATX in enhancing sensory signal transmission through visual circuitry, and may yield new insights for understanding the pathophysiology of certain cognitive disorders and inform development of improved therapeutic treatments for these conditions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127596PMC
http://dx.doi.org/10.1037/a0033563DOI Listing

Publication Analysis

Top Keywords

mph atx
12
light stimuli
12
male rats
8
sensory signal
8
therapeutic treatments
8
assays attention
8
responses light
8
primary response
8
mph
5
atx
5

Similar Publications

Few biological or clinical predictors guide medication selection and/or dosing for attention-deficit/hyperactivity disorder (ADHD). Accumulating data suggest that genetic factors may contribute to clinically relevant pharmacodynamic (e.g.

View Article and Find Full Text PDF
Article Synopsis
  • - This study investigated how stopping ADHD medication (methylphenidate) affects brain activity in youths, aiming to help clinicians decide on discontinuation.
  • - Analyzed data from 14 children (mostly males) showed improved ADHD-Rating Scores after medication was stopped, with specific brain regions like the prefrontal cortex showing activation during cognitive tasks.
  • - Findings indicate that certain brain functions change after stopping medication, suggesting that some children can manage ADHD symptoms without ongoing treatment.
View Article and Find Full Text PDF

This study aimed to examine switch from first-line methylphenidate (MPH) to lisdexamfetamine (LDX) in school-aged children with attention-deficit/hyperactivity disorder (ADHD). This is a retrospective observational study based on systematic review of patient records of all children (7-13 years) diagnosed with ADHD and referred to a Danish specialized outpatient clinic. The study included 394 children switching from MPH to LDX as either second-line or third-line treatment (atomoxetine [ATX] as second-line treatment) during the study period from April 1, 2013, to November 5, 2019.

View Article and Find Full Text PDF

Background And Objective: Methylphenidate (MPH) and atomoxetine (ATX) are the most common medications used to treat attention-deficit hyperactivity disorder (ADHD) in China; however, despite this, there is still a paucity of studies comparing their efficacy and safety, particularly for different characteristics. To address the lack of research, a real-world prospective cohort study was conducted to examine these properties of MPH and ATX, and to analyze correlations associated with age, sex, and different ADHD presentation.

Methods: Children with ADHD meeting the eligibility criteria were recruited from January 2016 to July 2021.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates how the stimulant methylphenidate (MPH) and non-stimulant atomoxetine (ATX) affect various brain cells and related genes in Drosophila melanogaster after observing increased locomotor activity (hyperactivity) from both drugs.
  • - Using single-cell RNA sequencing, they identified 28 major cell types in the adult Drosophila brain, noting significant transcriptional changes from MPH and ATX, with MPH affecting dopamine receptor genes more strongly than ATX.
  • - MPH also inhibited genes related to other neurotransmitter receptors and signaling molecules, particularly for Glu and GABA, indicating it has a broader impact on neurochemistry compared to ATX.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!